Correlation Between Immunic and Fate Therapeutics
Can any of the company-specific risk be diversified away by investing in both Immunic and Fate Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunic and Fate Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Immunic and Fate Therapeutics, you can compare the effects of market volatilities on Immunic and Fate Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunic with a short position of Fate Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunic and Fate Therapeutics.
Diversification Opportunities for Immunic and Fate Therapeutics
0.91 | Correlation Coefficient |
Almost no diversification
The 3 months correlation between Immunic and Fate is 0.91. Overlapping area represents the amount of risk that can be diversified away by holding Immunic and Fate Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fate Therapeutics and Immunic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunic are associated (or correlated) with Fate Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fate Therapeutics has no effect on the direction of Immunic i.e., Immunic and Fate Therapeutics go up and down completely randomly.
Pair Corralation between Immunic and Fate Therapeutics
Given the investment horizon of 90 days Immunic is expected to generate 0.53 times more return on investment than Fate Therapeutics. However, Immunic is 1.89 times less risky than Fate Therapeutics. It trades about -0.18 of its potential returns per unit of risk. Fate Therapeutics is currently generating about -0.14 per unit of risk. If you would invest 143.00 in Immunic on September 23, 2024 and sell it today you would lose (43.00) from holding Immunic or give up 30.07% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Strong |
Accuracy | 100.0% |
Values | Daily Returns |
Immunic vs. Fate Therapeutics
Performance |
Timeline |
Immunic |
Fate Therapeutics |
Immunic and Fate Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Immunic and Fate Therapeutics
The main advantage of trading using opposite Immunic and Fate Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunic position performs unexpectedly, Fate Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fate Therapeutics will offset losses from the drop in Fate Therapeutics' long position.Immunic vs. Fate Therapeutics | Immunic vs. Sana Biotechnology | Immunic vs. Caribou Biosciences | Immunic vs. Arcus Biosciences |
Fate Therapeutics vs. Atara Biotherapeutics | Fate Therapeutics vs. Sana Biotechnology | Fate Therapeutics vs. Caribou Biosciences | Fate Therapeutics vs. Arcus Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Complementary Tools
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |